course, everyone. you with call joining our for call Thank financial morning, quarter. session. of us our over our for good to-date, off up And so public before can Andrew, a And we as results conference business Bob. company. first review the overview open for the you, progress Q&A the quarterly Thank I'll Great. an call for call today's third today start a will to and turning then of he
We customers the System started. the an of U.S. company's as our history, commercial let's phase entered initial in Pure-Vu to marked that said, hospital by exciting of get shipments recently With our
to for on focused GI to anaemia, are prep as customers undergoing inadequate to procedures. significant these and bowel procedures, hospitalization colonoscopy patients delayed reminder, using XX% that even need conditions, Inadequate impatient leads resulting for currently This for infection of abdominal address providers. principally to remains System lower and prior preparation all the a canceled, pain. As emergency colonoscopy, in such Pure-Vu both bowel undiagnosed aborted inpatient unmet costs affects or increased bleed, patients and a prolonged an up
first the to inadequate The to control the the overcome visualization. hands Pure-Vu prep to time. and quality It safely rapidly clean the the of physicians bowel System puts power of high into colonoscopy and challenges allows physician achieve procedure for the during the colon
length clinical colonoscopies nursing are result, reducing in the both on an that inpatient patients demonstrated are are ensure time, we million studies and thereby the hospitals. million System improving year. XX its the performed up There Pure-Vu burden approximately bed makes of performed turnover every U.S., to colonoscopies the staff. that stay, in benefit As inpatient X.X over the and which and colonoscopies reducing have offers completed the Outside a estimate U.S. we several procedures clear overall XX% ability in of on estimated million X.X
System this large we unique to for global challenges has long-term, for Motus opportunity establish new Pure-Vu the believe GI standard-of-care Over prep the the a bowel inpatient as market.
into the procedures. into adjacent expand upper well market to opportunities follow-on see as GI outpatient as also We
been Since and exciting to commercial diligently this our commercial designed inflection a get it’s point. to optimize for quickly update, I detailed joining took this I as planning on important the Before team provide success. CEO one to and key GI ago, launch Motus we path year executing think review the to I have milestones
Mark in of of President Pomeranz, Officer. addition together the role leading deep Pure-Vu as First, top our the put the Israel great who asset development and assumed R&D me commercial and a company, leadership team the approval incredible Operating our advanced organization. previously regulatory System, a team has significantly of be CEO our tier company, we’ve to and led well Chief resources partner Mark been clinical as operations. to and with the to regulatory manufacturing to continues an bolstering
of also Peters Steve Global Regulatory and Affairs. into Quality as executives joined recently Vice President We roles. the Strategy; joined Vice of hired team leadership George and two important key Marketing Bosrock as our President and
device joined of appointment a team medical Jeff sales Hutchison, Commercial the Vice medical leading our Operations, several professionals with of led was and of from by who global device us Sales September President the Finally, sales seasoned in division expanded GI company.
XX our additions, and years than and to customer geographically proven now of situated GI largest allow team optimal these medtech opportunities. in sales believe proximity more we to averages our are experience With
market crystallized go-to-market Next, and we completed our assessment detailed a strategy.
to We that we as well have where highest profiles in focus order recurring adoption the help utilization carefully our the and may as both we’ll have and analyzed achieve launch as segmented in generating growth. streams procedure revenue future driving patient believe company success in well as and accounts sustainable
more more assessment, this commercial procedures initially per average a than which focusing X,XXX our market I'll on the with we in launch conduct moment. from hospital hospital networks, detail discuss anywhere are XXX year, inpatient Based on in detailed larger to colonoscopy
clinical in multi-center year. this preparing generate to This milestone study data. completed our through REDUCE launch inpatient key robust earlier strategy established was was we last the The
Pure-Vu showed may to after standard-of-care. compared improvement statically significant you cleanliness REDUCE recall, the bowel As in the use as study
market There delivering these XX% of Specifically, aware that is patients the improved to of at in Pure-Vu capable of adequate demonstrated today outcomes. we rate from technology preparation the that bowel are use that baseline. is no following XX%
and all key use milestone reliability. of major improves XXXX This most The single our as the well importance scopes, Pure-Vu as GENX our in system Motus improvements loading for and of brings commercial of receiving to was generation to cannot to improved success. It set shipments for GENX incorporates further mobility, another system of course now use available navigation, clearance I commencing commercially enhancements rapid me these and cleansing of FDA future handling workstation outstanding which time, maintaining our upgrade of our incorporates also GI second important system. up ease that positioning overstate sleeve while commercial onto facilitates which in the capabilities.
As the previously announced, our first early October. of commercial began System in placements Pure-Vu
had reason and feedback real focus on characteristics, adopter of ease given to on they're These is generation The their out early the was are initial sites Our first Pure-Vu use. experience system including adopter that are hospitals early hospitals. because world with using system. experience rolling ergonomics our rapid prior in handling we us providing its previous
into has feedback to and accelerate critical the extremely additional early This been and feedback as the positive. QX, throughout To-date, we of course hospitals is of beyond. our XXXX remainder deployment
In early pipeline growth help and long-term just position us initial adopter large can these for which opportunities hospitals, addition commercial is focused sustainable in of that to targets on substantial value I market, our this high outlined.
hospitals to target the we of as From of to a of we Pure-Vu macro to represents inpatient strategic the if rollout X,XXX System year, you market. in between which than that at hospital have hospital this a colonoscopy with which perform our perspective, approximately look procedures greater customers, future many potential are XXX X,XXX targeting, all proceed already the the and we opportunity
With we strategy understanding, are currently of executing. me that let commercial provide outline the an
to through This become one purchases go identifying to standard medical champion for most this System building is Pure-Vu relationships through two has required stage, physicians, who Committee typically be Value the and a the a Analysis System with hospitals. our process successful within it team Pure-Vu process. starts First, To will with in review. device sales VAC the key
this XX days to can we start VAC days one a to rental contains XXX has variety brief While choice from hospitals options. offer to device approval an the finish. between vary, final capital purchase, of of then and or approved, process anywhere which make require most or can evaluation The acquisition outright of Once purchase. they utilize our the to programs a hospital lease prior
deeper [XX] meaningful hospitals pipeline, conduct directly now evaluation. If these their importantly, number we've our resubmitted we with hospitals. more VACs Most a approval progress into made System a bit have to Pure-Vu received to we target of than and have the the engaged with an dive
or move in XXXX. we and A tenured evaluations, team, elaborate making the further armed tools believe is which Integrated winning economic quarter these into percentage affiliated process is we stage, these on to if IDN powerful process at leasing, not the clinical and with most, through progress. our early part high and the Following hospitals. Networks, fourth consists numerous or additional Delivery rental VAC in larger very of To of this customers targets, importance purchase expect all, positive utmost are initial of good
hospitals sister which site, an IDN. gain that adoption in provide to within of that to approval flagship is easier strategy are Our we same pathway then part the
their have to very have they since our and introducing new either; doing brief purchased of System evaluation on now funnel while sites for report workstation process; their market. to a proceed device prior budget first is using sales completed that evaluations the in VAC who the loan capital pleased through XX early targets. the customers three, of their hospitals our approval or launch, to our medical are implementation. approximately purchased submitted a These approval; In combination system; adopter have for entire weeks their six and VAC utilized sleeves one, four, to Pure-Vu two, is purchase early for typical are submitting in I'm to This companies being solution short-term as
of belief sleeves important time focused to Initially, disposable per ramp purposes, growth through five utilization Motus at site. modeling our In per every opportunity driving long-term for the is approximately expect therefore XX revenue System we over to it’s to model, month procedures that customers we of workstation. terms will GI our be sale Pure-Vu our to the on and recognize for
be One driver will expansion GI a of utilization staff. the hospital within
XX activation product to implement account. a has GI account account to may use our a objective training and establishing the the and two system doctors specialist out broad of agreed-upon our for an within and of have regular range from staff hospital Pure-Vu only physicians can doctors. staff Once clinical includes can cases. account place, their to example, additional that System the GI that which customer an the experience, of lead at Pure-Vu inpatient a to new limit the will program, For on protocol is Pure-Vu initial five a hospital workstation with utilization This three in
additional execution which in our growing to program will quarter We believe our sleeves. disposable the of each lead sales will activation lead account of to turn utilization
the are we launch our it provide with specific pleased While initial the in is to system, too early of guidance. uptake
metrics penetration market. of However, of we key quarters on after we plan into the commercial experience, the to System get several the share Pure-Vu
centers. medical of generating the committed this EXPEDITE announced are investigators world-class to investigator of we to clinical week, System leading we ahead, in Medical study additional initiation Center. Looking with Pure-Vu Boston at an being evidence Earlier the the collaboration initiated and benefit conducted
study regimen at as successful assess outpatient inpatient hospital. of System’s use time the cases is bowel well minimize order to for performed to population to ability further for The in Pure-Vu primarily the conventional a accelerate to preparation the the as designed colonoscopy the
an no this the resonate bowel would successful bleed diagnose possible. I and customers to our immediately. emergency available, new of was not that case the treated accounts bowel procedures all my conduced ultimately Pure-Vu. The I system bedside unit. want exemplifies care Pure-Vu bleeds identified and System, approach to immediate inherently to prep. source adoption Without arrive an out our now and System have up of had the been globally. sharing ago, patient the by Unfortunately has A across our like few had U.S. ICU, the the common to real patient This the physician power then intensive an help rolled that likely hemorrhage then been world of Pure-Vu prep remarks this the GI weeks the worldwide at treatment. close their had think Knowing with pre-procedural admitted to could hospital. GI drive one truly into too colonoscopy, the It’s they cases and patient us and are patient the and rapid obstacle
have the through of patients We impact are technology. our the all we inspired on can by positive use
I will to to now our Andrew turn financials over for discuss the quarter. Andrew? the call third
